Details of the Drug Combination

General Information of Drug Combination (ID: DC2QMO2)

Drug Combination Name
Atorvastatin Methylprednisolone
Indication
Disease Entry Status REF
Thyroid Associated Ophthalmopathy Phase 2 [1]
Component Drugs Atorvastatin   DMF28YC Methylprednisolone   DM4BDON
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Atorvastatin
Disease Entry ICD 11 Status REF
Acute coronary syndrome BA41 Approved [2]
Angina pectoris BA40 Approved [2]
Arteriosclerosis BD40 Approved [2]
Cardiovascular disease BA00-BE2Z Approved [3]
Coronary atherosclerosis N.A. Approved [2]
Hypercholesterolaemia 5C80.0 Approved [2]
Hyperlipidemia 5C80.Z Approved [4]
Hyperlipidemia, familial combined, LPL related N.A. Approved [2]
Hypertriglyceridemia 5C80.1 Approved [2]
Inflammation 1A00-CA43.1 Approved [2]
Non-insulin dependent diabetes 5A11 Approved [2]
Psoriasis EA90 Approved [2]
Type-1/2 diabetes 5A10-5A11 Approved [2]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [5]
Stroke 8B20 Investigative [2]
Venous thromboembolism BD72 Investigative [2]
Atorvastatin Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
HMG-CoA reductase (HMGCR) TTPADOQ HMDH_HUMAN Inhibitor [12]
HUMAN MYD88NF-kappa-B proinflammatory pathway (MYD88-NFKB pathway) TTDJB68 N.A. Inhibitor [13]
------------------------------------------------------------------------------------
Atorvastatin Interacts with 7 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [14]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [15]
Organic anion transporting polypeptide 1A2 (SLCO1A2) DTE2B1D SO1A2_HUMAN Substrate [16]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [17]
Organic anion transporting polypeptide 2B1 (SLCO2B1) DTPFTEQ SO2B1_HUMAN Substrate [18]
Monocarboxylate transporter 1 (SLC16A1) DT342ZG MOT1_HUMAN Substrate [19]
Monocarboxylate transporter 2 (SLC16A7) DTLT3UG MOT2_HUMAN Substrate [20]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 DTP(s)
Atorvastatin Interacts with 6 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [21]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Metabolism [22]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [23]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Metabolism [24]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Metabolism [25]
UDP-glucuronosyltransferase 1A3 (UGT1A3) DEF2WXN UD13_HUMAN Metabolism [26]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DME(s)
Atorvastatin Interacts with 93 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Stromelysin-1 (MMP3) OTGBI74Z MMP3_HUMAN Increases ADR [27]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Decreases Activity [28]
Apolipoprotein E (APOE) OTFOWL2H APOE_HUMAN Decreases Expression [29]
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) OTRT3F3U HMDH_HUMAN Increases Expression [30]
Kinesin-like protein KIF6 (KIF6) OTDH3MR4 KIF6_HUMAN Increases Response To Substance [31]
ATP-binding cassette sub-family C member 2 (ABCC2) OTJSIGV5 MRP2_HUMAN Decreases Activity [32]
Serum paraoxonase/arylesterase 1 (PON1) OTD0Z2XO PON1_HUMAN Increases Expression [33]
Cytochrome P450 2B6 (CYP2B6) OTOYO4S7 CP2B6_HUMAN Increases Expression [34]
Nuclear receptor subfamily 1 group I member 3 (NR1I3) OTS3SGH7 NR1I3_HUMAN Increases Activity [34]
Phospholipid-transporting ATPase ABCA1 (ABCA1) OT94G6BQ ABCA1_HUMAN Decreases Expression [29]
Sterol 26-hydroxylase, mitochondrial (CYP27A1) OT649C01 CP27A_HUMAN Decreases Expression [29]
Angiopoietin-2 (ANGPT2) OTEQK65P ANGP2_HUMAN Increases Expression [9]
Urokinase-type plasminogen activator (PLAU) OTX0QGKK UROK_HUMAN Decreases Expression [9]
Thrombospondin-1 (THBS1) OT0ECWK3 TSP1_HUMAN Decreases Expression [9]
Heme oxygenase 1 (HMOX1) OTC1W6UX HMOX1_HUMAN Increases Expression [9]
Nitric oxide synthase 3 (NOS3) OTLDT7NR NOS3_HUMAN Increases Expression [9]
Catalase (CAT) OTHEBX9R CATA_HUMAN Increases Activity [35]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [36]
Nuclear receptor subfamily 1 group I member 2 (NR1I2) OTC5U0N5 NR1I2_HUMAN Increases Expression [37]
Solute carrier family 2, facilitated glucose transporter member 2 (SLC2A2) OTBL2W7R GTR2_HUMAN Decreases Expression [37]
Hexokinase-4 (GCK) OTR3Q0NN HXK4_HUMAN Decreases Expression [37]
Toll-like receptor 4 (TLR4) OTP7ML3S TLR4_HUMAN Increases Expression [38]
Toll-like receptor 2 (TLR2) OTGO5P4R TLR2_HUMAN Increases Expression [38]
Prothrombin (F2) OTNFSM49 THRB_HUMAN Decreases Activity [39]
Myc proto-oncogene protein (MYC) OTPV5LUK MYC_HUMAN Decreases Expression [40]
Low-density lipoprotein receptor (LDLR) OTH559LU LDLR_HUMAN Increases Expression [30]
Insulin (INS) OTZ85PDU INS_HUMAN Increases Expression [41]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Decreases Expression [10]
Interleukin-2 receptor subunit alpha (IL2RA) OT0MWCHG IL2RA_HUMAN Affects Expression [38]
Collagen alpha-1(I) chain (COL1A1) OTI31178 CO1A1_HUMAN Increases Expression [42]
C-reactive protein (CRP) OT0RFT8F CRP_HUMAN Decreases Expression [43]
Transferrin receptor protein 1 (TFRC) OT8ZPBDL TFR1_HUMAN Affects Expression [38]
Osteocalcin (BGLAP) OTK1YLWQ OSTCN_HUMAN Increases Expression [42]
Apolipoprotein B-100 (APOB) OTH0UOCZ APOB_HUMAN Decreases Expression [44]
Superoxide dismutase , mitochondrial (SOD2) OTIWXGZ9 SODM_HUMAN Affects Expression [45]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases Expression [40]
Eukaryotic translation initiation factor 2 subunit 1 (EIF2S1) OTM0GDTP IF2A_HUMAN Increases Phosphorylation [46]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Decreases Expression [47]
Endothelin-1 (EDN1) OTZCACEG EDN1_HUMAN Decreases Expression [48]
Intercellular adhesion molecule 1 (ICAM1) OTTOIX77 ICAM1_HUMAN Increases Expression [10]
Integrin beta-1 (ITGB1) OT6G1IAR ITB1_HUMAN Increases Expression [49]
Rho-related GTP-binding protein RhoC (RHOC) OTOLE1FT RHOC_HUMAN Decreases Localization [50]
Monocyte differentiation antigen CD14 (CD14) OT83GJ47 CD14_HUMAN Decreases Expression [51]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [52]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Decreases Expression [47]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [52]
Integrin alpha-M (ITGAM) OTAG6HWU ITAM_HUMAN Decreases Expression [51]
Coagulation factor V (F5) OTDMZ3LT FA5_HUMAN Decreases Activity [39]
Bone morphogenetic protein 2 (BMP2) OT23T37S BMP2_HUMAN Increases Expression [42]
C-C motif chemokine 2 (CCL2) OTAD2HEL CCL2_HUMAN Decreases Expression [47]
E-selectin (SELE) OT33RZWY LYAM2_HUMAN Increases Expression [10]
Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) OT2D9DOV TNR1A_HUMAN Decreases Expression [48]
Integrin alpha-X (ITGAX) OTOGIMHE ITAX_HUMAN Decreases Expression [51]
Tumor necrosis factor receptor superfamily member 5 (CD40) OT5YU2XB TNR5_HUMAN Decreases Expression [38]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Decreases Phosphorylation [52]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Decreases Phosphorylation [52]
Interleukin-12 subunit alpha (IL12A) OTDQT8GI IL12A_HUMAN Decreases Expression [53]
CD40 ligand (CD40LG) OT75Z6A6 CD40L_HUMAN Decreases Expression [54]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Increases Expression [46]
Nicotinamide N-methyltransferase (NNMT) OTFM38GU NNMT_HUMAN Increases Expression [55]
T-lymphocyte activation antigen CD86 (CD86) OTJCSBPC CD86_HUMAN Decreases Expression [38]
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA) OTTOMI8J PK3CA_HUMAN Decreases Expression [40]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [52]
Cyclin-dependent kinase inhibitor 1B (CDKN1B) OTNY5LLZ CDN1B_HUMAN Increases Expression [52]
Tumor necrosis factor ligand superfamily member 6 (FASLG) OTZARCHH TNFL6_HUMAN Increases Expression [56]
Fatty acid synthase (FASN) OTFII9KG FAS_HUMAN Increases Expression [57]
Importin subunit alpha-1 (KPNA2) OTU7FOE6 IMA1_HUMAN Affects Localization [58]
Microsomal triglyceride transfer protein large subunit (MTTP) OTNUVSDT MTP_HUMAN Decreases Expression [30]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Increases Activity [59]
Transforming protein RhoA (RHOA) OT6YOJ9N RHOA_HUMAN Decreases Activity [52]
Rho-related GTP-binding protein RhoB (RHOB) OTHQFQF7 RHOB_HUMAN Increases Expression [50]
Cytochrome c (CYCS) OTBFALJD CYC_HUMAN Affects Localization [45]
E3 ubiquitin-protein ligase Mdm2 (MDM2) OTOVXARF MDM2_HUMAN Increases Expression [40]
CD83 antigen (CD83) OT1V4WQF CD83_HUMAN Decreases Expression [38]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Expression [60]
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) OT2YYI1A MCL1_HUMAN Decreases Expression [52]
Peroxisome proliferator-activated receptor alpha (PPARA) OTK095PP PPARA_HUMAN Decreases Expression [61]
Sterol regulatory element-binding protein 2 (SREBF2) OTBXUNPL SRBP2_HUMAN Increases Localization [57]
5'-AMP-activated protein kinase catalytic subunit alpha-1 (PRKAA1) OT7TNF0L AAPK1_HUMAN Increases Activity [55]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Increases Activity [59]
Serum paraoxonase/arylesterase 2 (PON2) OT55NCTD PON2_HUMAN Increases Expression [62]
Adiponectin (ADIPOQ) OTNX23LE ADIPO_HUMAN Decreases Expression [41]
Nuclear factor erythroid 2-related factor 2 (NFE2L2) OT0HENJ5 NF2L2_HUMAN Decreases Expression [45]
Bcl-2 homologous antagonist/killer (BAK1) OTDP6ILW BAK_HUMAN Increases Expression [60]
NAD-dependent protein deacetylase sirtuin-1 (SIRT1) OTAYZMOY SIR1_HUMAN Increases Phosphorylation [55]
Eukaryotic translation initiation factor 2-alpha kinase 3 (EIF2AK3) OT0DZGY4 E2AK3_HUMAN Increases Response To Substance [46]
Tumor necrosis factor ligand superfamily member 10 (TNFSF10) OT4PXBTA TNF10_HUMAN Increases Response To Substance [63]
Liver carboxylesterase 1 (CES1) OT9L0LR8 EST1_HUMAN Increases ADR [27]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Increases Transport [64]
Solute carrier organic anion transporter family member 2B1 (SLCO2B1) OTERJ4VQ SO2B1_HUMAN Increases Uptake [65]
Solute carrier organic anion transporter family member 1B1 (SLCO1B1) OTNEN8QK SO1B1_HUMAN Decreases Transport [66]
Solute carrier organic anion transporter family member 1B3 (SLCO1B3) OTOM3BUH SO1B3_HUMAN Increases Uptake [65]
Sister chromatid cohesion protein DCC1 (DSCC1) OTPUVLZT DCC1_HUMAN Affects Response To Substance [67]
------------------------------------------------------------------------------------
⏷ Show the Full List of 93 DOT(s)
Indication(s) of Methylprednisolone
Disease Entry ICD 11 Status REF
Acute adrenal insufficiency N.A. Approved [6]
Acute asthma CA23 Approved [6]
Addison disease 5A74.0 Approved [6]
Allergic rhinitis CA08.0 Approved [6]
Angioedema 4A00.15 Approved [6]
Aspiration pneumonitis N.A. Approved [6]
Autoimmune haemolytic anaemia 3A20 Approved [6]
Bursitis N.A. Approved [6]
Cerebral edema 8D60.1 Approved [6]
Chronic graft versus host disease N.A. Approved [6]
Congenital adrenal hyperplasia 5A71.01 Approved [6]
Crohn disease DD70 Approved [6]
Dermatitis herpetiformis EB44 Approved [6]
Diamond-Blackfan anemia N.A. Approved [6]
Disorder of orbital region N.A. Approved [6]
Epicondylitis N.A. Approved [6]
Erythema multiforme N.A. Approved [6]
Exanthem N.A. Approved [6]
Fever MG26 Approved [6]
Granuloma annulare N.A. Approved [6]
Inflammatory bowel disease DD72 Approved [6]
Ischemia-reperfusion injury DB98.B Approved [6]
Leukemia N.A. Approved [6]
Lupus nephritis 4A40.0Y Approved [6]
Microscopic polyangiitis N.A. Approved [6]
Miliary tuberculosis N.A. Approved [6]
Multiple sclerosis 8A40 Approved [6]
Mycosis fungoides 2B01 Approved [6]
Myeloproliferative neoplasm 2A20 Approved [6]
Pneumocystis pneumonia CA40.20 Approved [6]
Primary cutaneous T-cell lymphoma N.A. Approved [6]
Psoriasis EA90 Approved [6]
Psoriatic arthritis FA21 Approved [6]
Rheumatic heart disease N.A. Approved [6]
Rheumatoid arthritis FA20 Approved [3]
Sarcoidosis 4B20.5 Approved [6]
Seasonal allergic rhinitis CA08.01 Approved [6]
Serum sickness N.A. Approved [6]
Severe asthma CA23 Approved [6]
Skin disease EA00-EM0Z Approved [6]
Solid tumour/cancer 2A00-2F9Z Approved [3]
Systemic lupus erythematosus 4A40.0 Approved [6]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [7]
Acquired thrombocytopenia N.A. Investigative [6]
Asthma CA23 Investigative [6]
Beta-thalassemia major N.A. Investigative [6]
Classic Hodgkin lymphoma N.A. Investigative [6]
Follicular lymphoma 2A80 Investigative [6]
Perennial allergic rhinitis CA08.03 Investigative [6]
Spinal cord injury ND51.2 Investigative [8]
Synovitis N.A. Investigative [6]
Trichinellosis N.A. Investigative [6]
Methylprednisolone Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Glucocorticoid receptor (NR3C1) TTYRL6O GCR_HUMAN Modulator [70]
------------------------------------------------------------------------------------
Methylprednisolone Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [71]
------------------------------------------------------------------------------------
Methylprednisolone Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [72]
------------------------------------------------------------------------------------
Methylprednisolone Interacts with 87 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Decreases Expression [73]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Increases Expression [74]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Decreases Expression [68]
CCN family member 1 (CCN1) OTKJBEMD CCN1_HUMAN Increases Expression [68]
Phospholipid phosphatase 3 (PLPP3) OTSSF7BK PLPP3_HUMAN Decreases Expression [68]
Interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) OTPGHZB9 IFIT3_HUMAN Decreases Expression [68]
Calmegin (CLGN) OTEWVFQV CLGN_HUMAN Decreases Expression [68]
D-3-phosphoglycerate dehydrogenase (PHGDH) OT1LMRTG SERA_HUMAN Decreases Expression [68]
Receptor-interacting serine/threonine-protein kinase 2 (RIPK2) OT0KMIYQ RIPK2_HUMAN Decreases Expression [68]
Gasdermin-E (GSDME) OT1ZWY32 GSDME_HUMAN Decreases Expression [68]
Toll-like receptor 2 (TLR2) OTGO5P4R TLR2_HUMAN Decreases Expression [68]
CCN family member 5 (CCN5) OTADU8JJ CCN5_HUMAN Increases Expression [68]
Antiviral innate immune response receptor RIG-I (RIGI) OTFIIC43 RIGI_HUMAN Decreases Expression [68]
2'-5'-oligoadenylate synthase 1 (OAS1) OT8ZLOCY OAS1_HUMAN Decreases Expression [68]
Collagen alpha-1(I) chain (COL1A1) OTI31178 CO1A1_HUMAN Increases Expression [68]
Superoxide dismutase , mitochondrial (SOD2) OTIWXGZ9 SODM_HUMAN Decreases Expression [68]
Ubiquitin-like protein ISG15 (ISG15) OT53QQ7N ISG15_HUMAN Decreases Expression [68]
Thrombospondin-1 (THBS1) OT0ECWK3 TSP1_HUMAN Increases Expression [68]
Asparagine synthetase (ASNS) OT8R922G ASNS_HUMAN Decreases Expression [68]
Hepatocyte growth factor receptor (MET) OT7K55MU MET_HUMAN Decreases Expression [68]
Steryl-sulfatase (STS) OTXTJQPC STS_HUMAN Increases Expression [68]
Neuromedin-B (NMB) OT4NLN6H NMB_HUMAN Decreases Expression [68]
Stromelysin-2 (MMP10) OTJDWW8Q MMP10_HUMAN Decreases Expression [68]
Growth-regulated alpha protein (CXCL1) OT3WCTZV GROA_HUMAN Decreases Expression [68]
Interferon alpha-inducible protein 6 (IFI6) OTWOOAM4 IFI6_HUMAN Decreases Expression [68]
Interferon-induced protein with tetratricopeptide repeats 1 (IFIT1) OTXOQDSG IFIT1_HUMAN Decreases Expression [68]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Decreases Expression [68]
Interleukin-1 receptor antagonist protein (IL1RN) OT308CBE IL1RA_HUMAN Decreases Expression [68]
C-X-C motif chemokine 2 (CXCL2) OTEJCYMY CXCL2_HUMAN Decreases Expression [68]
C-X-C motif chemokine 3 (CXCL3) OTSL94KH CXCL3_HUMAN Decreases Expression [68]
Interferon-induced GTP-binding protein Mx1 (MX1) OT6X8G5T MX1_HUMAN Decreases Expression [68]
Fibulin-1 (FBLN1) OT5MHHOP FBLN1_HUMAN Increases Expression [68]
Atypical chemokine receptor 3 (ACKR3) OTA6GA4F ACKR3_HUMAN Decreases Expression [68]
11-beta-hydroxysteroid dehydrogenase 1 (HSD11B1) OTO7FJA9 DHI1_HUMAN Decreases Expression [68]
Adenosine receptor A2a (ADORA2A) OTVRBZ0I AA2AR_HUMAN Decreases Expression [68]
CCN family member 2 (CCN2) OTC39NSU CCN2_HUMAN Increases Expression [68]
Myristoylated alanine-rich C-kinase substrate (MARCKS) OT7N056G MARCS_HUMAN Decreases Expression [68]
Guanylate-binding protein 1 (GBP1) OTUM7RPJ GBP1_HUMAN Decreases Expression [68]
Prostaglandin G/H synthase 2 (PTGS2) OT75U9M4 PGH2_HUMAN Decreases Expression [68]
Macrophage metalloelastase (MMP12) OT9Z7LHM MMP12_HUMAN Decreases Expression [68]
Interferon alpha-inducible protein 27, mitochondrial (IFI27) OTI2XGIT IFI27_HUMAN Decreases Expression [68]
Signal transducer and activator of transcription 1-alpha/beta (STAT1) OTLMBUZ6 STAT1_HUMAN Decreases Expression [68]
Regulator of G-protein signaling 4 (RGS4) OTG94HHL RGS4_HUMAN Decreases Expression [68]
Prolargin (PRELP) OT9EEBUJ PRELP_HUMAN Increases Expression [68]
Spermine synthase (SMS) OT8JYKNH SPSY_HUMAN Decreases Expression [68]
C-X-C chemokine receptor type 4 (CXCR4) OTUFSBX2 CXCR4_HUMAN Decreases Expression [68]
C-C motif chemokine 20 (CCL20) OTUCJY4N CCL20_HUMAN Decreases Expression [68]
Interferon-induced 35 kDa protein (IFI35) OTV9RZ53 IN35_HUMAN Decreases Expression [68]
DNA-binding protein inhibitor ID-3 (ID3) OTUULW5Z ID3_HUMAN Increases Expression [68]
Tumor necrosis factor alpha-induced protein 2 (TNFAIP2) OTRZH80H TNAP2_HUMAN Decreases Expression [68]
Aldehyde oxidase (AOX1) OT2FZP6H AOXA_HUMAN Increases Expression [68]
Bone marrow stromal antigen 2 (BST2) OTU4LCJV BST2_HUMAN Decreases Expression [68]
EGF-containing fibulin-like extracellular matrix protein 1 (EFEMP1) OTZVUOOB FBLN3_HUMAN Increases Expression [68]
Neuronal membrane glycoprotein M6-b (GPM6B) OT8Q1582 GPM6B_HUMAN Increases Expression [68]
Laminin subunit beta-3 (LAMB3) OTFPU6W8 LAMB3_HUMAN Decreases Expression [68]
Nidogen-2 (NID2) OTHC33FF NID2_HUMAN Increases Expression [68]
Signal transducer and activator of transcription 4 (STAT4) OTAK3VFR STAT4_HUMAN Decreases Expression [68]
2'-5'-oligoadenylate synthase-like protein (OASL) OTZ05YRP OASL_HUMAN Decreases Expression [68]
Bcl-2-related protein A1 (BCL2A1) OTWRYSNA B2LA1_HUMAN Decreases Expression [68]
Lymphocyte antigen 6E (LY6E) OTMG16BZ LY6E_HUMAN Decreases Expression [68]
Interferon-induced protein 44-like (IFI44L) OTXKORJP IF44L_HUMAN Decreases Expression [68]
E3 ubiquitin-protein ligase RNF19B (RNF19B) OTYCWKBP RN19B_HUMAN Decreases Expression [68]
Amphoterin-induced protein 2 (AMIGO2) OTPAIT1O AMGO2_HUMAN Decreases Expression [68]
Probable E3 ubiquitin-protein ligase HERC6 (HERC6) OT7G9PQE HERC6_HUMAN Decreases Expression [68]
Equilibrative nucleobase transporter 1 (SLC43A3) OTR60ZLA S43A3_HUMAN Decreases Expression [68]
Interferon-induced protein 44 (IFI44) OTOKSZVA IFI44_HUMAN Decreases Expression [68]
S-adenosylmethionine-dependent nucleotide dehydratase RSAD2 (RSAD2) OTCA9WCM RSAD2_HUMAN Decreases Expression [68]
Nuclear receptor subfamily 4 group A member 3 (NR4A3) OTPBE9R1 NR4A3_HUMAN Decreases Expression [68]
Type II iodothyronine deiodinase (DIO2) OTGPNSLH IOD2_HUMAN Increases Expression [68]
Interferon regulatory factor 7 (IRF7) OTC1A2PQ IRF7_HUMAN Decreases Expression [68]
Interferon-stimulated gene 20 kDa protein (ISG20) OTCWRJJW ISG20_HUMAN Decreases Expression [68]
Interferon-induced helicase C domain-containing protein 1 (IFIH1) OTZA2AHA IFIH1_HUMAN Decreases Expression [68]
Anthrax toxin receptor 1 (ANTXR1) OT5W1GPC ANTR1_HUMAN Increases Expression [68]
Interleukin-23 subunit alpha (IL23A) OTYO99HC IL23A_HUMAN Decreases Expression [68]
NADH dehydrogenase 1 alpha subcomplex subunit 4-like 2 (NDUFA4L2) OTK0PG7R NUA4L_HUMAN Decreases Expression [68]
E3 ISG15--protein ligase HERC5 (HERC5) OTZ5PR39 HERC5_HUMAN Decreases Expression [68]
Cystine/glutamate transporter (SLC7A11) OTKJ6PXW XCT_HUMAN Decreases Expression [68]
Hypoxia-inducible lipid droplet-associated protein (HILPDA) OTEID3ZM HLPDA_HUMAN Decreases Expression [68]
2'-5'-oligoadenylate synthase 3 (OAS3) OT6E5FYS OAS3_HUMAN Decreases Expression [68]
Coagulation factor VIII (F8) OTH6XHDU FA8_HUMAN Increases Expression [69]
Myelin basic protein (MBP) OTFZCEDB MBP_HUMAN Decreases Expression [75]
Glial fibrillary acidic protein (GFAP) OTQ01ZAS GFAP_HUMAN Decreases Expression [75]
5-hydroxytryptamine receptor 3A (HTR3A) OTAIV1AK 5HT3A_HUMAN Decreases Activity [76]
Tyrosine aminotransferase (TAT) OT2CJ91O ATTY_HUMAN Increases ADR [27]
Glucocorticoid receptor (NR3C1) OTCI2YDI GCR_HUMAN Increases ADR [27]
Thrombopoietin (THPO) OTO73DZ2 TPO_HUMAN Increases ADR [27]
P-selectin (SELP) OTWR90PK LYAM3_HUMAN Increases ADR [27]
------------------------------------------------------------------------------------
⏷ Show the Full List of 87 DOT(s)

References

1 ClinicalTrials.gov (NCT03110848) Effects of Atorvastatin in Graves' Orbitopathy (GO)
2 Atorvastatin FDA Label
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 205945.
5 ClinicalTrials.gov (NCT04380402) Atorvastatin in COVID-19. U.S. National Institutes of Health.
6 Methylprednisolone FDA Label
7 ClinicalTrials.gov (NCT04341038) Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With COVID-19 Lung Injury
8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7088).
9 Atorvastatin affects several angiogenic mediators in human endothelial cells. Endothelium. 2005 Sep-Dec;12(5-6):233-41.
10 Markers of inflammation, thrombosis and endothelial activation correlate with carotid IMT regression in stable coronary disease after atorvastatin treatment. Nutr Metab Cardiovasc Dis. 2009 Sep;19(7):481-90. doi: 10.1016/j.numecd.2008.10.003. Epub 2009 Jan 26.
11 Simvastatin reduces VCAM-1 expression in human umbilical vein endothelial cells exposed to lipopolysaccharide. Inflamm Res. 2012 May;61(5):485-91. doi: 10.1007/s00011-012-0435-9. Epub 2012 Jan 15.
12 Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64.
13 Statin therapy in COVID-19 infection. Eur Heart J Cardiovasc Pharmacother. 2020 Apr 29. pii: pvaa042.
14 Tarascon Pocket Pharmacopoeia 2018 Classic Shirt-Pocket Edition.
15 Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta. 2009 Jul;405(1-2):49-52.
16 Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem Pharmacol. 2010 Dec 1;80(11):1746-53.
17 FDA Drug Development and Drug Interactions
18 Human platelets express organic anion-transporting peptide 2B1, an uptake transporter for atorvastatin. Drug Metab Dispos. 2009 May;37(5):1129-37.
19 H+-coupled nutrient, micronutrient and drug transporters in the mammalian small intestine. Exp Physiol. 2007 Jul;92(4):603-19.
20 Monocarboxylate Transporters in Drug Disposition: Role in the Toxicokinetics and Toxicodynamics of the Drug of Abuse GHB.
21 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
22 Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid. Drug Metab Dispos. 2007 Aug;35(8):1315-24.
23 Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharm Res. 2006 Mar;23(3):506-12.
24 Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers.
25 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
26 UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone. Mol Diagn Ther. 2013 Aug;17(4):233-7.
27 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
28 Effect of atorvastatin and fluvastatin on the metabolism of midazolam by cytochrome P450 in vitro. Anaesthesia. 2005 Aug;60(8):747-53.
29 Effects of rosiglitazone and atorvastatin on the expression of genes that control cholesterol homeostasis in differentiating monocytes. Biochem Pharmacol. 2006 Feb 28;71(5):605-14.
30 Differential regulation of apolipoprotein B secretion from HepG2 cells by two HMG-CoA reductase inhibitors, atorvastatin and simvastatin. J Lipid Res. 1999 Jun;40(6):1078-89.
31 [Association of a polymorphic marker Trp719Arg of KIF6 gene with effects of atorvastatin and simvastatin in patients with early ischemic heart disease]. Kardiologiia. 2011;51(9):4-12.
32 Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005 Apr;33(4):537-46.
33 Effect of pitavastatin on transactivation of human serum paraoxonase 1 gene. Metabolism. 2005 Feb;54(2):142-50.
34 Identification of HMG-CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor. Drug Metab Dispos. 2005 Jul;33(7):924-9.
35 The effect of statins on lipids peroxidation and activities of antioxidants enzymes in patients with dyslipidemia. Przegl Lek. 2006;63(9):738-42.
36 A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci. 2013 Nov;136(1):216-41.
37 Involvement of pregnane X receptor in the impaired glucose utilization induced by atorvastatin in hepatocytes. Biochem Pharmacol. 2016 Jan 15;100:98-111.
38 Differential effects of statins on relevant functions of human monocyte-derived dendritic cells. J Leukoc Biol. 2006 Mar;79(3):529-38. doi: 10.1189/jlb.0205064. Epub 2005 Dec 30.
39 Atorvastatin and quinapril inhibit blood coagulation in patients with coronary artery disease following 28 days of therapy. J Thromb Haemost. 2006 Nov;4(11):2397-404. doi: 10.1111/j.1538-7836.2006.02165.x. Epub 2006 Aug 14.
40 Atorvastatin induces MicroRNA-145 expression in HEPG2 cells via regulation of the PI3K/AKT signalling pathway. Chem Biol Interact. 2018 May 1;287:32-40. doi: 10.1016/j.cbi.2018.04.005. Epub 2018 Apr 6.
41 Additive beneficial effects of atorvastatin combined with amlodipine in patients with mild-to-moderate hypertension. Int J Cardiol. 2011 Feb 3;146(3):319-25. doi: 10.1016/j.ijcard.2009.07.002. Epub 2009 Aug 3.
42 Simvastatin and atorvastatin enhance gene expression of collagen type 1 and osteocalcin in primary human osteoblasts and MG-63 cultures. J Cell Biochem. 2007 Aug 15;101(6):1430-8. doi: 10.1002/jcb.21259.
43 Effects of atorvastatin on inflammation and oxidative stress. Heart Vessels. 2005 Jul;20(4):133-6. doi: 10.1007/s00380-005-0833-9.
44 Use of atorvastatin in hyperlipidemic hypertensive renal transplant recipients. Pediatr Nephrol. 2002 Jul;17(7):540-3. doi: 10.1007/s00467-002-0860-z. Epub 2002 May 25.
45 Atorvastatin induces mitochondrial dysfunction and cell apoptosis in HepG2 cells via inhibition of the Nrf2 pathway. J Appl Toxicol. 2019 Oct;39(10):1394-1404. doi: 10.1002/jat.3825. Epub 2019 Aug 18.
46 Inhibition of autophagy enhances anticancer effects of atorvastatin in digestive malignancies. Cancer Res. 2010 Oct 1;70(19):7699-709. doi: 10.1158/0008-5472.CAN-10-1626. Epub 2010 Sep 28.
47 Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol. 2002 Jul 1;22(7):1194-9. doi: 10.1161/01.atv.0000022694.16328.cc.
48 The effects of atorvastatin (10 mg) on systemic inflammation in heart failure. Am J Cardiol. 2005 Dec 15;96(12):1699-704. doi: 10.1016/j.amjcard.2005.07.092. Epub 2005 Oct 28.
49 Statins regulate alpha2beta1-integrin expression and collagen I-dependent functions in human vascular smooth muscle cells. J Cardiovasc Pharmacol. 2003 Jan;41(1):89-96. doi: 10.1097/00005344-200301000-00012.
50 Combination of atorvastatin and celecoxib synergistically induces cell cycle arrest and apoptosis in colon cancer cells. Int J Cancer. 2008 May 1;122(9):2115-24. doi: 10.1002/ijc.23315.
51 Integrin expression on monocytes and lymphocytes in unstable angina short term effects of atorvastatin. Rom J Intern Med. 2007;45(2):193-9.
52 RhoA GTPase inactivation by statins induces osteosarcoma cell apoptosis by inhibiting p42/p44-MAPKs-Bcl-2 signaling independently of BMP-2 and cell differentiation. Cell Death Differ. 2006 Nov;13(11):1845-56. doi: 10.1038/sj.cdd.4401873. Epub 2006 Feb 10.
53 Treatment with atorvastatin alters the ratio of interleukin-12/interleukin-10 gene expression [corrected]. Eur J Clin Invest. 2003 Jan;33(1):88-91. doi: 10.1046/j.1365-2362.2003.01105.x.
54 Effect of atorvastatin on circulating proinflammatory T-lymphocyte subsets and soluble CD40 ligand in patients with stable coronary artery disease--a randomized, placebo-controlled study. Am Heart J. 2006 Jan;151(1):139. doi: 10.1016/j.ahj.2005.10.006.
55 Atorvastatin and pravastatin stimulate nitric oxide and reactive oxygen species generation, affect mitochondrial network architecture and elevate nicotinamide N-methyltransferase level in endothelial cells. J Appl Toxicol. 2021 Jul;41(7):1076-1088. doi: 10.1002/jat.4094. Epub 2020 Oct 19.
56 Decreased circulating Fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis: normalization by atorvastatin. J Am Coll Cardiol. 2004 Apr 7;43(7):1188-94. doi: 10.1016/j.jacc.2003.10.046.
57 Effect of atorvastatin, simvastatin, and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells. Biochem Pharmacol. 2001 Dec 1;62(11):1545-55. doi: 10.1016/s0006-2952(01)00790-0.
58 Effect of Ivermectin and Atorvastatin on Nuclear Localization of Importin Alpha and Drug Target Expression Profiling in Host Cells from Nasopharyngeal Swabs of SARS-CoV-2- Positive Patients. Viruses. 2021 Oct 15;13(10):2084. doi: 10.3390/v13102084.
59 Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. Carcinogenesis. 2005 May;26(5):883-91. doi: 10.1093/carcin/bgi036. Epub 2005 Feb 10.
60 Atorvastatin mediates increases in intralesional BAX and BAK expression in human end-stage abdominal aortic aneurysms. Can J Physiol Pharmacol. 2009 Nov;87(11):915-22. doi: 10.1139/y09-085.
61 Regulation mechanism of ABCA1 expression by statins in hepatocytes. Eur J Pharmacol. 2011 Jul 15;662(1-3):9-14. doi: 10.1016/j.ejphar.2011.04.043. Epub 2011 May 1.
62 Decreased macrophage paraoxonase 2 expression in patients with hypercholesterolemia is the result of their increased cellular cholesterol content: effect of atorvastatin therapy. Arterioscler Thromb Vasc Biol. 2004 Jan;24(1):175-80. doi: 10.1161/01.ATV.0000104011.88939.06. Epub 2003 Oct 30.
63 Regulation of apoptosis in human melanoma and neuroblastoma cells by statins, sodium arsenite and TRAIL: a role of combined treatment versus monotherapy. Apoptosis. 2011 Dec;16(12):1268-84.
64 Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter. Pharm Res. 2000 Feb;17(2):209-15. doi: 10.1023/a:1007525616017.
65 The influence of oral antidiabetic drugs on cellular drug uptake mediated by hepatic OATP family members. Basic Clin Pharmacol Toxicol. 2013 Apr;112(4):244-50. doi: 10.1111/bcpt.12031. Epub 2012 Dec 6.
66 Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics. 2005 Jul;15(7):513-22.
67 Identification of target and pathway of aspirin combined with Lipitor treatment in prostate cancer through integrated bioinformatics analysis. Toxicol Appl Pharmacol. 2022 Oct 1;452:116169. doi: 10.1016/j.taap.2022.116169. Epub 2022 Aug 1.
68 Antirheumatic drug response signatures in human chondrocytes: potential molecular targets to stimulate cartilage regeneration. Arthritis Res Ther. 2009;11(1):R15.
69 von Willebrand factor and thrombin activation in children with newly diagnosed acute lymphoblastic leukemia: an impact of peripheral blasts. Pediatr Blood Cancer. 2010 Jul 1;54(7):963-9. doi: 10.1002/pbc.22466.
70 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
71 Secretory transport of methylprednisolone possibly mediated by P-glycoprotein in Caco-2 cells. Biol Pharm Bull. 2002 Mar;25(3):393-6.
72 Cytochrome P450 enzyme regulation by glucocorticoids and consequences in terms of drug interaction. Expert Opin Drug Metab Toxicol. 2014 Mar;10(3):425-35.
73 Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction. Drug Metab Dispos. 2006 Oct;34(10):1742-8.
74 Protective effect of methylprednisolone on paraquat-induced A549 cell cytotoxicity via induction of efflux transporter, P-glycoprotein expression. Toxicol Lett. 2012 Jan 25;208(2):101-7. doi: 10.1016/j.toxlet.2011.10.019. Epub 2011 Oct 31.
75 A prominent elevation of glial fibrillary acidic protein in the cerebrospinal fluid during relapse in neuromyelitis optica. Tohoku J Exp Med. 2008 May;215(1):55-9. doi: 10.1620/tjem.215.55.
76 Inhibitory effect of glucocorticoids on human-cloned 5-hydroxytryptamine3A receptor expressed in xenopus oocytes. Anesthesiology. 2004 Sep;101(3):660-5. doi: 10.1097/00000542-200409000-00014.